This Project's primary goal is to develop the use of gamma inulin-based adjuvants as safe and effective adjuvants for use in vaccines against Category A, B and C bioterrorism pathogens. As adjuvants cannot receive regulatory approval in their own right but only as part of a vaccine composition, a further objective is to develop at least one vaccine against a Category A, B or C pathogen by combining gamma inulin-based adjuvant with pathogen derived proteins or peptides. Specific components of the project include the physico-chemical characterization, and optimization of inulin-based adjuvants for use in bioterrorism subunit vaccines, determination of the mechanisms of action of inulin-based adjuvants, thereby creating the ability to develop further novel nontoxic adjuvants that utilize similar immuno-stimulatory pathways, validation of the biological activity of inulin-based adjuvants in combination with model pathogen-derived antigens (e.g. Q Fever, Shigella, flaviviruses, small pox, SARS), proof of concept studies demonstrating vaccine protection in validated animal infection models and pre-clinical safety and toxicology studies to enable inulin-based adjuvants to advance into phase 1 human trials. Although pure recombinant antigens although undoubtedly safer than whole organism vaccines, a major problem is their general lack of immunogenicity. This has created a major demand for more potent yet safe adjuvants not associated with unacceptable toxicity. Hence the urgent need for a well tolerated and effective adjuvant capable of boosting both cellular and humoral immunity. Inulin-based adjuvants offer just such advantages and should work well in combination with bioterrorism vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI061142-04
Application #
7487808
Study Section
Special Emphasis Panel (ZAI1-AR-M (M1))
Program Officer
Khambaty, Farukh M
Project Start
2005-08-01
Project End
2010-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
4
Fiscal Year
2008
Total Cost
$1,439,143
Indirect Cost
Name
Flinders University of South Australia
Department
Type
DUNS #
756172482
City
Adelaide
State
Country
Australia
Zip Code
5001
Wang, Lixin; Barclay, Thomas; Song, Yunmei et al. (2017) Investigation of the biodistribution, breakdown and excretion of delta inulin adjuvant. Vaccine 35:4382-4388
Honda-Okubo, Yoshikazu; Rajapaksha, Harinda; Sajkov, Dimitar et al. (2017) Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine. Hum Vaccin Immunother 13:1-11
Barclay, Thomas G; Rajapaksha, Harinda; Thilagam, Alagu et al. (2016) Physical characterization and in silico modeling of inulin polymer conformation during vaccine adjuvant particle formation. Carbohydr Polym 143:108-15
Hess, Jessica A; Zhan, Bin; Torigian, April R et al. (2016) The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice. PLoS Negl Trop Dis 10:e0004797
Sakala, Isaac G; Honda-Okubo, Yoshikazu; Fung, Johnson et al. (2016) Influenza immunization during pregnancy: Benefits for mother and infant. Hum Vaccin Immunother 12:3065-3071
Davtyan, Hayk; Zagorski, Karen; Rajapaksha, Harinda et al. (2016) Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and A? pathological molecules. Sci Rep 6:28912
Gordon, David L; Sajkov, Dimitar; Honda-Okubo, Yoshikazu et al. (2016) Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant. Vaccine 34:3780-6
Petrovsky, Nikolai; Cooper, Peter D (2015) Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. Vaccine 33:5920-6
Li, Lei; Honda-Okubo, Yoshikazu; Li, Connie et al. (2015) Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine. PLoS One 10:e0132003
Cooper, Peter D; Rajapaksha, K Harinda; Barclay, Thomas G et al. (2015) Inulin crystal initiation via a glucose-fructose cross-link of adjacent polymer chains: atomic force microscopy and static molecular modelling. Carbohydr Polym 117:964-72

Showing the most recent 10 out of 41 publications